Get started
Author

Santiago Ponce

Observed names: Ponce, Santiago, S Ponce, S. Ponce, Santiago Aix Ponce, Santiago Ponce Aix, Santiago Ponce-Aix
Observed institutions: North Sichuan Medical University, Universidad Complutense de Madrid, Centre National de la Recherche Scientifique, Institut national de recherche en sciences et technologies du numérique, Inserm, Chinese University of Hong Kong, Sichuan University, Université Paris-Saclay, Guangdong General Hospital, West China Medical Center of Sichuan University, Hospital Universitario La Paz, Institut Gustave Roussy, Hospital Clínico San Carlos, Research Institute Hospital 12 de Octubre, First Affiliated Hospital of Sichuan Medical University, Spanish National Cancer Research Centre, Peking University Cancer Hospital, Hospital Universitario 12 De Octubre, Hospital Universitario Puerta de Hierro Majadahonda, Institut Català d'Oncologia, Prince of Wales Hospital, Centro de Investigación Biomédica en Red, Guangdong Academy of Medical Sciences, Centro de Investigación Biomédica en Red de Cáncer, Laboratoire d'Imagerie Biomédicale Multimodale Paris-Saclay, Fondation Gustave Roussy
ORCID: 0000-0002-2289-4709
Observed ORCID: 0000-0002-2289-4709
OpenAlex ID: A5111777596
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Current Challenges in Cancer Treatment
2016 · Jon Zugazagoitia, Cristiano Guedes, et al. · Clinical Therapeutics · 926
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
2018 · Laura Mezquita, Edouard Auclin, et al. · JAMA Oncology · 913
PDF
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
2020 · José Trigo, Vivek Subbiah, et al. · The Lancet Oncology · 486
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
2023 · Mariano Provencio, Ernest Nadal, et al. · New England Journal of Medicine · 485
PDF
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
2015 · Jean-Charles Soria, Yi-Long Wu, et al. · The Lancet Oncology · 411
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
2017 · Tony S.K. Mok, Sang-We Kim, et al. · Journal of Clinical Oncology · 179
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
2022 · D. Araujo, A. Greystoke, et al. · Annals of Oncology · 106
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors
2020 · Iván Márquez-Rodas, Federico Longo, et al. · Science Translational Medicine · 88
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
2016 · Mark A. Socinski, Frederic J. Kaye, et al. · Clinical Lung Cancer · 86
PDF
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
2023 · A. Bayle, L. Belcaid, et al. · Annals of Oncology · 76
The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.
2014 · Jon Zugazagoitia, Ana Belen Enguita, et al. · PubMed · 73
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
2022 · Hedy L Kindler, Silvia Novello, et al. · The Lancet Oncology · 68
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)
2022 · A. Bayle, F. Peyraud, et al. · Annals of Oncology · 64
PDF
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
2020 · M. Dómine, T. Moran, et al. · Clinical & Translational Oncology · 60
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
2021 · Laura Mezquita, Isabel Preeshagul, et al. · European Journal of Cancer · 57
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
2022 · Mariona Riudavets, Edouard Auclin, et al. · European Journal of Cancer · 56
Blood Predictive Biomarkers for Patients With Non–small-cell Lung Cancer Associated With Clinical Response to Nivolumab
2019 · M. Teresa Agulló-Ortuño, Óscar Gómez-Martín, et al. · Clinical Lung Cancer · 53
Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib: the Phase Iii, Randomised Impress Study
2014 · T.S.K. Mok, Y. Wu, et al. · Annals of Oncology · 46
PDF
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
2020 · Vivek Subbiah, Luis Paz-Ares, et al. · Lung Cancer · 41
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
2022 · J. Chen, F. Facchinetti, et al. · Annals of Oncology · 39
PDF
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
2023 · Santiago Ponce, Susana Cedrés, et al. · Journal for ImmunoTherapy of Cancer · 37
PDF
Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants
2022 · Tala Tayoun, Vincent Faugeroux, et al. · JCI Insight · 30
PDF
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer
2019 · Eva María Ciruelos, María Nieves Díaz, et al. · European Journal of Cancer Care · 30
PDF
Works count: 239
Citation count: 7,899
H-index: 26
I10-index: 48
Year
Topic
Type